» Articles » PMID: 17175524

A Novel Inhibitor of Mycobacterium Tuberculosis Pantothenate Synthetase

Overview
Journal J Biomol Screen
Publisher Sage Publications
Date 2006 Dec 19
PMID 17175524
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Pantothenate synthetase (PS; EC 6.3.2.1), encoded by the panC gene, catalyzes the essential adenosine triphosphate (ATP)-dependent condensation of D-pantoate and beta-alanine to form pantothenate in bacteria, yeast, and plants; pantothenate is a key precursor for the biosynthesis of coenzyme A (CoA) and acyl carrier protein (ACP). Because the enzyme is absent in mammals and both CoA and ACP are essential cofactors for bacterial growth, PS is an attractive chemotherapeutic target. An automated high-throughput screen was developed to identify drugs that inhibit Mycobacterium tuberculosis PS. The activity of PS was measured spectrophotometrically through an enzymatic cascade involving myokinase, pyruvate kinase, and lactate dehydrogenase. The rate of PS ATP utilization was quantitated by the reduction of absorbance due to the oxidation of NADH to NAD+ by lactate dehydrogenase, which allowed for an internal control to detect interference from compounds that absorb at 340 nm. This coupled enzymatic reaction was used to screen 4080 compounds in a 96-well format. This discussion describes a novel inhibitor of PS that exhibits potential as an antimicrobial agent.

Citing Articles

Unearthing phytochemicals as natural inhibitors for pantothenate synthetase in : A computational approach.

Chouhan M, Tiwari P, Mishra R, Gupta S, Kumar M, Abdullah Almuqri E Front Pharmacol. 2024; 15:1403900.

PMID: 39135797 PMC: 11317409. DOI: 10.3389/fphar.2024.1403900.


Pantothenate kinase: A promising therapeutic target against pathogenic species.

Hasnat S, Hoque M, Mahbub M, Sakif T, Shahinuzzaman A, Islam T Heliyon. 2024; 10(14):e34544.

PMID: 39130480 PMC: 11315101. DOI: 10.1016/j.heliyon.2024.e34544.


: Pathogenesis and therapeutic targets.

Yang J, Zhang L, Qiao W, Luo Y MedComm (2020). 2023; 4(5):e353.

PMID: 37674971 PMC: 10477518. DOI: 10.1002/mco2.353.


The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development.

Yan W, Zheng Y, Dou C, Zhang G, Arnaout T, Cheng W Mol Biomed. 2022; 3(1):48.

PMID: 36547804 PMC: 9780415. DOI: 10.1186/s43556-022-00106-y.


Inhibitors of pantothenate synthetase of - a medicinal chemist perspective.

Suresh A, Srinivasarao S, Khetmalis Y, Nizalapur S, Sankaranarayanan M, Sekhar K RSC Adv. 2022; 10(61):37098-37115.

PMID: 35521286 PMC: 9057165. DOI: 10.1039/d0ra07398a.